首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes
【24h】

The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes

机译:佐剂AS01诱导的淋巴免疫反应:肌内和皮下免疫途径的比较

获取原文
获取原文并翻译 | 示例
       

摘要

The liposome-based adjuvant AS01 incorporates two immune stimulants, 3-O-desacyl-4'-monophosphoryl lipid A and the saponin QS-21. AS01 is under investigation for use in several vaccines in clinical development. i.m. injection of AS01 enhances immune cell activation and dendritic cell (DC) Ag presentation in the local muscle-draining lymph node. However, cellular and Ag trafficking in the lymphatic vessels that connect an i.m. injection site with the local lymph node has not been investigated. The objectives of this study were: 1) to quantify the in vivo cellular immune response induced by AS01 in an outbred ovine model, 2) to develop a lymphatic cannulation model that directly collects lymphatic fluid draining the muscle, and 3) to investigate the function of immune cells entering and exiting the lymphatic compartments after s.c. or i.m. vaccination with AS01 administered with hepatitis B surface Ag (HBsAg). We show that HBsAg-AS01 induces a distinct immunogenic cellular signature within the blood and draining lymphatics following both immunization routes. We reveal that MHCIIhigh migratory DCs, neutrophils, and monocytes can acquire Ag within muscle and s.c. afferent lymph, and that HBsAg-AS01 uniquely induces the selective migration of Ag-positive neutrophils, monocytes, and an MHCIIhigh DC-like cell type out of the lymph node via the efferent lymphatics that may enhance Ag-specific immunity. We report the characterization of the immune response in the lymphatic network after i.m. and s.c. injection of a clinically relevant vaccine, all in real time using a dose and volume comparable with that administered in humans.
机译:基于脂质体的佐剂AS01结合了两种免疫刺激剂,即3-O-去酰基-4'-单磷酰基脂质A和皂苷QS-21。目前正在研究将AS01用于临床开发中的几种疫苗。我注射AS01可增强免疫细胞活化和树突状细胞(DC)在局部引流淋巴结中的Ag表现。但是,连接i.m.的淋巴管中的细胞和Ag转运。注射部位有局部淋巴结尚未调查。这项研究的目的是:1)量化近交绵羊模型中由AS01诱导的体内细胞免疫应答,2)建立直接收集流向肌肉的淋巴液的淋巴管模型,以及3)研究其功能sc后进入和离开淋巴室的免疫细胞的数量或我接种乙型肝炎表面抗原(HBsAg)的AS01疫苗。我们显示,HBsAg-AS01会在两种免疫途径之后,在血液和引流淋巴管内诱导出独特的免疫原性细胞标志。我们揭示了MHCII高迁移DC,嗜中性粒细胞和单核细胞可以在肌肉和s.c中获得Ag。 HBsAg-AS01独特地诱导Ag阳性嗜中性粒细胞,单核细胞和MHCIIhigh DC样细胞类型通过传出的淋巴管有选择地迁移出淋巴结,从而增强Ag特异性免疫。我们报告了I.m后淋巴网络中免疫反应的特征。和s.c.实时注射与临床有关的疫苗,所使用的剂量和体积可与人类所用的剂量和体积相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号